Match!

Ranking medical innovations according to perceived health benefit

Published on Jun 1, 2016in Health policy and technology
· DOI :10.1016/j.hlpt.2016.02.009
Jilles M. Fermont4
Estimated H-index: 4
(University of Oxford),
Karla Douw1
Estimated H-index: 1
(UT: University of Twente)
+ 1 AuthorsMaarten Joost IJzerman41
Estimated H-index: 41
(UT: University of Twente)
Abstract
Objectives In 2001, Fuchs and Sox published a landmark study on the relative importance for patients of thirty preselected medical innovations in the United States. About a decade later, we replicated the study in the Netherlands in response to the continuing debate on rising healthcare costs. The aims were to provide an updated list of medical innovations, categorise these according to their impact and novelty, provide a ranking according to the perceived health benefit by Dutch clinical and health technology experts, and draw conclusions for health technology policy making at a macro-level. Methods A search to identify medical innovations introduced in healthcare systems between 1990 and 2010 was performed in Medline. The authors categorised the innovations and disagreement was resolved by majority vote. Dutch health technology- and clinical experts from national agencies and medical societies ranked the innovations by means of best-worst scaling experiments in an online survey. Results Forty-one technologies (16 pharmaceuticals and 25 non-pharmaceuticals) were included. Of these, nine were categorised as big ticket technology, 24 as add-on and ten as new. Sixty-six clinical and health technology experts ranked these technologies. Self-monitoring of blood glucose and biological therapies for autoimmune diseases ranked highest. Conclusions Study limitations prevent making robust conclusions, however, results indicate that many of the identified innovations are add-on technologies, increasing health care cost at only marginal health benefit. If add-on technologies are the trend and healthcare systems aim to provide value for money, policies might need to be adjusted and research and development strategies should be informed at an earlier stage of technological development.
  • References (21)
  • Citations (1)
📖 Papers frequently viewed together
10 Citations
8 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References21
Newest
#2Sue SimpsonH-Index: 13
Last. Marina CerboH-Index: 4
view all 18 authors...
The first toolkit for the identification and assessment of new and emerging health technologies was developed by members of the EuroScan International Network and published in 2009. Five years later this revised toolkit continues to focus on methods that are integral to an early awareness and alert (EAA) system. It is once again a collaborative piece of work to which all members have contributed with new information based on their experiences being added. The main stages involved in EAA systems ...
13 Citations
This report reviews the history of U.S. health care spending and discusses potential explanations for the slowing in the rate of increase in health care expenditures in recent years. Strategies to control future health care costs are also discussed.
35 CitationsSource
Abstract Background: Self-monitoring of blood glucose (SMBG) is a proven tool to improve glycemic control, even if it might increase direct costs for diabetes management. In Italy, the purchase, prescription rules and responsibilities, and distribution of testing strips per type of patient are managed differently in each of the 20 Italian regions. The Italian scientific societies for diabetes (Societa Italiana Diabetologia [SID] and Associazione Medici Diabetologi [AMD]) have issued validated gu...
13 CitationsSource
#1Maarten Joost IJzerman (UT: University of Twente)H-Index: 41
#2Lotte M.G. Steuten (UT: University of Twente)H-Index: 16
Worldwide, billions of dollars are invested in medical product development and there is an increasing pressure to maximize the revenues of these investments. That is, governments need to be informed about the benefits of spending public resources, companies need more information to manage their product development portfolios and even universities may need to direct their research programmes in order to maximize societal benefits. Assuming that all medical products need to be adopted by the heavi...
78 CitationsSource
#1A. St JohnH-Index: 15
#2Wendy A. Davis (UWA: University of Western Australia)H-Index: 30
Last. Timothy M. E. Davis (UWA: University of Western Australia)H-Index: 65
view all 4 authors...
Abstract Aims To review the recent literature relating to the role of self-monitoring of blood glucose (SMBG) and glycemic control. Methods Medline and EMBASE databases were searched between 1996 and June 2008 using terms that included diabetes mellitus, self-care, and blood glucose self monitoring. Both experimental and nonexperimental studies with HbA 1c as an outcome measure were included. A meta-analysis was performed on randomized controlled trials (RCTs) in type 2 diabetes which met the in...
56 CitationsSource
#1Ping Zhang (CDC: Centers for Disease Control and Prevention)H-Index: 39
#2Xinzhi Zhang (CDC: Centers for Disease Control and Prevention)H-Index: 29
Last. Gregory A. Nichols (KP: Kaiser Permanente)H-Index: 40
view all 7 authors...
Abstract Aims To estimate the global health expenditure on diabetes among people aged 20–79 years for the years 2010 and 2030. Methods Country-by-country expenditures for 193 countries, expressed in United States Dollars (USD) and in International Dollars (ID), were estimated based on the country's age–sex specific diabetes prevalence and population estimates, per capita health expenditures, and health expenditure ratios per person with and without diabetes. Diabetes prevalence was estimated fro...
629 CitationsSource
There is increased interest in the use of best–worst scaling (BWS) as a method of preference elicitation in health. However, the method is undergoing rapid development in several fields, making dissemination of new insights challenging. Furthermore, there are two types of BWS that have hitherto received little interest in health, but that are uniquely placed to address certain issues. This article offers an update of the state of play of BWS, presents original research to illustrate new methods ...
132 CitationsSource
#1Bert ArnrichH-Index: 22
#2Oscar MayoraH-Index: 19
Last. Gerhard TrösterH-Index: 57
view all 4 authors...
OBJECTIVES: The aging of the population creates pressure on the healthcare systems in various ways. A massive increase of chronic disease conditions and age-related illness are predicted as the dominant forces driving the future health care. The objective of this paper is to present future research demands in pervasive healthcare with the goal to meet the healthcare challenges by paving the way for a pervasive, user-centered and preventive healthcare model. METHODS: This paper presents recent me...
106 CitationsSource
#1Joan Costa-FontH-Index: 33
#2Christophe CourbageH-Index: 13
Last. Alistair McGuireH-Index: 45
view all 3 authors...
Technological change in healthcare has led to huge improvements in health services and the health status of populations. It is also pinpointed as the main driver of healthcare expenditure. Although offering remarkable benefits, changes in technology are not free and often entail significant financial, as well as physical or social risks. These need to be balanced out in the setting of government regulations, insurance contracts, and individuals' decisions to use and consume certain technologies....
3 Citations
Disruptive innovation has brought affordability and convenience to customers in a variety of industries. However, health care remains expensive and inaccessible to many because of the lack of business-model innovation. This paper explains the theory of disruptive innovation and describes how disruptive technologies must be matched with innovative business models. The authors present a framework for categorizing and developing business models in health care, followed by a discussion of some of th...
234 CitationsSource
Cited By1
Newest
#1Maarten Joost IJzerman (UT: University of Twente)H-Index: 41
#2Hendrik Koffijberg (UT: University of Twente)H-Index: 24
Last. Murray Krahn (U of T: University of Toronto)H-Index: 50
view all 4 authors...
Early health technology assessment is increasingly being used to support health economic evidence development during early stages of clinical research. Such early models can be used to inform research and development about the design and management of new medical technologies to mitigate the risks, perceived by industry and the public sector, associated with market access and reimbursement. Over the past 25 years it has been suggested that health economic evaluation in the early stages may benef...
18 CitationsSource